pubs.acs.org/joc

Towards Enantiomerically Pure Unnatural α -Amino Acids via Photoredox Catalytic 1,4-Additions to a Chiral Dehydroalanine

Paula Oroz, Claudio D. Navo, Alberto Avenoza, Jesús H. Busto, Francisco Corzana, Gonzalo Jiménez-Osés, and Jesús M. Peregrina*



enantiomerically pure carbon- β -substituted unnatural α -amino acids (UAAs), which could have a high potential for applications in chemical biology.

INTRODUCTION

Access to enantiopure unnatural α -amino acids (UAAs) remains a challenge in organic chemistry, especially those bearing side-chain diversity in their structure because they are common components of pharmaceuticals or medicinal chemistry targets.¹ Beyond applications to modulate the conformational space of peptides and then their biological functions, UAAs are particularly relevant in stereoselective synthesis as chiral ligands and auxiliaries. Thus, synthetic methodologies for generating libraries of diverse enantiomerically pure UAAs are valuable to access relevant molecules in the field of drug design and peptide chemistry.² In this regard, various methods have been described to generate enantiopure carbon- β -substituted UAA. However, until recent years, less attention has been paid to carbon nucleophilic 1,4-conjugate addition reactions to dehydroamino acids due to the difficult stereochemical control, especially at the α -carbon.³ Moreover, the use of highly reactive organometallic reagents such as organomagnesiun derivatives usually leads to mixtures of 1,4and 1,2-adducts⁴ as we have seen in this article (see Supporting Information, SI, Table S1). A few examples are reported in which the treatment of dehydroalanine derivatives (Dha) with anionic carbon species afforded carbon- β -substituted derivatives through asymmetric Michael addition reactions.⁵ On the other hand, current synthetic methodologies have focused on visible-light-mediated catalytic methods that offer the advantages of using mild conditions, which allow for selective and controlled reactions.⁶ Thus, very recently and employing a variety of precursors, several radical 1,4-conjugate additions to Dha derivatives by photoredox catalytic reactions have been deeply explored to synthesize racemic UAAs.⁷ However, only very few cases have been reported to obtain enantiopure UAAs or their precursors,⁸ allowing the incorporation of different alkyl or aryl radicals at β -carbon, and most of them involved the use of a modified chiral Dha termed Karady–Beckwith alkene.⁹ Hence, inspired by these works and following the methodology established by our group,¹⁰ we envisioned the synthesis of enantiopure UAAs by using our 2nd-generation chiral Dha 1 as the starting material in both anionic carbon nucleophilic 1,4-attack and radical carbon photoredox catalytic 1,4-conjugate addition (Scheme 1).

RESULTS AND DISCUSSION

First, we assayed the 1,4-conjugated addition of some carbanions, generated in situ from their corresponding precursors, to Dha 1 as a Michael acceptor, following our protocol described for S-, N-, or Se-nucleophiles.¹⁰ However, the scope was very limited (SI) because we only achieved good results with diethyl malonate 2a and a chiral bicyclic serine derivative 2b. In the first case, diethyl malonate 2a and Dha 1 were dissolved in dry tetrahydrofuran (THF) and lithium hexamethyldisilazide (LHMDS) was added at room temperature as a base (Conditions A, Scheme 2). The reaction was completed in 5 min and adduct 3a was obtained in 81% yield after purification by column chromatography. In the case of chiral bicyclic serine derivative 2b, the reaction conditions were similar, but the temperature had to be lowered to -78 °C to preserve the configuration of the substrate in the generated carbanion (Conditions C, Scheme 2), as we demonstrated

Received: July 26, 2022 Published: September 30, 2022





© 2022 The Authors. Published by American Chemical Society Scheme 1. Synthesis of Enantiopure Carbon-β-Substituted UAAs via 1,4-Conjugate Addition to Chiral Dehydroalanines

Previous work



previously.¹¹ Once the reaction was completed (5 min), the corresponding adduct **3b** was obtained in a 70% yield after purification. Particularly relevant was the latter reaction since the 1,4-adduct **3b** displays 6 stereogenic centers and, most importantly, the chirality of the two ones generated in the global process is totally stereocontrolled. Both reactions took place with excellent yields. Acid hydrolysis and decarboxylation of adduct **3a** yielded enantiomerically pure glutamic acid **4a**. Given the importance of deuterium amino acids in medicinal chemistry,^{8a,b,12} enantiomerically pure α -deuterated glutamic acid **4a–D** was synthesized by using a 9:1 mixture of 2-propanol-OD (ⁱPrOD) and anhydrous CH₂Cl₂ as a solvent in the Michael addition (Conditions *B*, Scheme 2) followed by hydrolysis of adduct **3a–D** (Scheme 2).

On the other hand, hydrolysis of adduct **3b** led to bis- α amino acid **4b** (Scheme 2), which is a 2,4-diaminoglutaric acid (Dag)¹³ featuring a chiral quaternary stereocenter. Chimeric



Scheme 2. Synthesis of Enantiopure Glutamic Acid Derivatives via Stereoselective Michael Additions to Chiral Dha 1

⁽¹⁾ Yields after column chromatography

pubs.acs.org/joc

amino acids are important scaffolds often used to stabilize 3D structures of peptides; therefore, this new amino acid can be regarded as a chimera that combines the steric and conformational properties of a α -alkyl-substituted Ser and Dag.¹⁴ In all adducts 3a, 3a–D, and 3b, the absolute configurations of the new stereogenic centers created in the 1,4-conjugate additions were assessed by two-dimensional nuclear Overhauser effect spectroscopy (2D-NOESY) experiments and confirmed, in the case of 3b, by X-ray crystallography (SI). In view of these results, the reaction mechanism is hypothesized to be similar to that proposed for S- or Se-nucleophilic 1,4-additions¹⁰ to Dha 1. The stereochemical outcome of these Michael reactions to Dha 1 suggests a conserved stereoinduction mechanism for the protonation of the enolate adduct formed after conjugate addition (SI).

To increase the scope of these 1,4-additions, we focused on the photoredox catalytic 1,4-additions to chiral Dha **1**. Following the methodology used by Wang^{8a} and Schubert,^{8b} we envisioned the addition of a decarboxylated radical, starting from readily available and inexpensive alkylcarboxylic acids to Dha **1**, including the α -deuterating version of the reaction. We first assayed the reaction between Boc-Gly (**2c**) and methyl 2acetamidoacrylate to test different conditions under blue lightemitting diode (LED) irradiation (SI, Table S2), and the better ones were transferred to chiral Dha **1**.

After testing several conditions using different solvents and catalysts (SI), the optimum conditions involved the use of Dha 1 (1.0 equiv), carboxylic acid 2c (1.2 equiv), Cs_2CO_3 (1.5 equiv) as a base, and 4CzIPN (0.05 equiv) as a catalyst in *N*,*N*-dimethylformamide (DMF) as a solvent at room temperature. Once the reaction was completed after 16 h of irradiation, we observed the clean formation of a single diastereomer, corresponding to adduct 3c (88% yield, Scheme 3).

The scope of the reaction was examined by reacting carboxylic acids 2c-n with Dha 1, which generated adducts **3c**-**n** in good yields (Scheme 3). In the case of α -deuterated derivative 3c-D (82% yield and 93% deuteration, Scheme 3), it was necessary to add a small quantity of $D_2O(50 \ \mu L)$ to the reaction. Besides carbamate-protected amine 2c, we explored several functionalities in the structure of carboxylic acids such as ether (2i), thioether (2j), and selenoether (2k), which were well-tolerated and afforded desired products 3i-k in excellent yields. The reaction of Dha 1 with benzylic and secondary alkylcarboxylic acids (2d, 2e, and 2h, respectively), as well as with other highly hindered tertiary alkylcarboxylic acids (2f and 2g), also gave excellent yields of adducts 3d-h (Scheme 3). In addition, the reaction with Boc-protected $\alpha_{,\alpha}$ disubstituted α -amino acids 2l and 2m gave excellent yields of adducts 31 and 3m, respectively. Finally, we assayed the photoredox reaction of Dha 1 with the important carboxylic acid 2n, which bears a reactive alkyne group in 1,3-dipolar cycloadditions. Therefore, the corresponding UAA derived from adduct 3n would be of application in bioconjugation chemistry. As expected, the reaction proceeds with an adequate yield (57%) of adduct 3n. However, and unfortunately, although this reaction works with 100% conversions with amino acids that present chirality at the α -carbon (Boc-L-Ala, Boc-L-Leu, or Boc-L-Pro), it is impossible to control the chirality of the generated radical, resulting in a mixture of adducts in similar ratios (SI). As an example, Scheme 4 shows the reaction of Dha 1 with Boc-L-Ala 20 to give the mixture of diastereomers 30.



Scheme 4. Photoredox Catalytic 1,4-Addition of Boc-L-Ala to Chiral Dha 1



Based on the above-described results, we propose that these photoredox catalytic Giese reactions proceed via the mechanism shown in Scheme 5. Initially, Cs_2CO_3 deprotonates the carboxylic acid 2, and once the photocatalyst [4CzIPN] is

Scheme 5. Mechanism for the Giese Reactions on Dha 1



excited by irradiation at 465–470 nm, the excited-state catalyst $[4CzIPN]^*$ led to decarboxylation to generate an alkyl radical (R[•]), which is added to the Dha 1 to afford radical intermediate 3[•]. This carbon radical is reduced to enolate 3⁻, which is trapped by a proton/deuterium to give the 1,4-adduct 3. Simultaneously, conversion of $[4CzIPN]^{\bullet-}$ to the [4CzIPN] catalyst completes the catalytic cycle.

In all adducts 3c-m, the absolute configurations of the new stereogenic centers created in the Giese reactions were assessed by 2D-NOESY experiments (SI). Alternatively, this structural feature was also determined by X-ray analysis of monocrystals of compound 3k (Figure 1a). As described above for the anionic 1,4-additions, the stereochemical outcome of these Giese reactions on Dha 1 indicates a highly conserved stereoinduction mechanism.

The proposed mechanism for the addition of *tert*-butyl (g^{\bullet}) , iso-propyl (h^{\bullet}) , and model ethyl (Et^{\bullet}) radicals to Dha 1 was studied computationally using the PCM(DMF)/M06-2X/6-31+G(d,p) method (SI, Figures S4-S6). The computed activation barriers for the Giese reaction were relatively low $(\Delta G^{\ddagger} \approx 11 \text{ kcal mol}^{-1})$ leading to stable radical intermediates **3**• ($\Delta G \approx -22$ kcal mol⁻¹) and enolate intermediates **3**⁻ (ΔG ≈ -36 kcal mol⁻¹) upon single-electron transfer (SET). In contrast to what was observed for β -thioenolates,^{10a} the calculated lowest-energy structures of β -alkylenolate intermediates (ultimately responsible for stereoselection) displayed low ($\theta = 6^{\circ}$ for less hindered **3Et**⁻) to negligible ($\theta < 1^{\circ}$ for $3g^{-}$ and $3h^{-}$) pyramidalization at the α -carbon (C3). A similar effect was observed for enolate $3a^-$ ($\theta = 4^\circ$). The steric hindrance between the bridgehead methyl group and the β substituent makes the latter tilt away, overcoming the native tendency of the bicyclic scaffold to yield pyramidalized enolates and resulting in an almost planar α -carbon. As a consequence, the usually more accessible convex face is completely shielded, favoring protonation by the concave face (Figure 1b and SI, Figure S6).

In fact, protonation of enolate $3\mathbf{g}^-$ with hydrogencarbonate (\mathbf{HCO}_3^-) as a proton source by the concave (re) face $(3\mathbf{g}^-\mathbf{TSprot}_re)$ induced a conformational change of the bicyclic scaffold to avoid steric clashes with the substituent at $C\beta$ upon $\mathrm{sp}^2 \to \mathrm{sp}^3$ rehybridization of $C\alpha$ (SI, Figure S7). Nevertheless, and in excellent agreement with the observed stereoselectivity, this reaction pathway is 2.6 kcal mol⁻¹ more favorable than protonation by the convex (si) face $(3\mathbf{g}^-\mathbf{TSprot}_si)$ due to significant repulsion between the hydrogencarbonate anion and both the bridgehead methyl





Figure 1. (a) ORTEP diagram of compound 3k, showing thermal ellipsoids at the 75% probability level. (b) Lowest-energy structure for enolate intermediate 3g- calculated with PCM(DMF)/M06-2X/6-31+G(d,p). θ represents the out-of-plane angle of C β with respect to the plane defined by C2, C3, and N4. Angles close to 0° correspond to planarity (i.e., negligible pyramidalization at C α). Relative activation barriers ($\Delta\Delta G^{\ddagger}$ in kcal mol⁻¹) for protonation with HCO₃⁻ by the *re* and *si* faces are indicated with green and red arrows, respectively (see the SI, Figure S7, for further details).

group and the substituent at $C\beta$ (Figures 1b and S7 in the SI). A similar trend is observed for the least stable rotamer of the enolate ($3g^{-}_{conf}2$), which already ca. 3 kcal mol⁻¹ higher in energy than $3g^{-}$ (SI, Figure S5), resulting hence in even higher activation energies for the protonation by either face ($\Delta\Delta G^{\ddagger} = 3-4$ kcal mol⁻¹) (SI, Figure S7).

Hydrolysis of adduct **3c** led to 2,4-diaminobutyric acid (Dab, **4c**) in a good yield (93%). Dab is an important UAA that appears in the structure of several polymyxin antibiotics. Besides, Dab is a neurotoxin with antitumor effects. ^{15,16} Using the same deuteration methodology, α -deuterated Dab **4c**-**D** was synthesized (89% yield and 89% deuteration, Scheme 6). Adducts **3d**, **3e**, **3g**, **3i**, and **3j** are precursors of L-homophenylalanine (Hph), 3-cyclohexylalanine (Cha), 3-*tert*-butylalanine (Tba), *O*-phenylhomoserine [Hse(*O*Ph)], and *S*-phenylhomocysteine [Hcy(*S*Ph)], respectively, which are relevant UAAs involved in different biological studies.^{17,18} Particularly significant is the adduct **3k** as the precursor of *Se*-phenylhomoselenocysteine [Hsc(*Se*Ph)], which is a selenoa-mino acid with potential use in native chemical ligation.¹⁹

The methodology reported herein deals with a new chiral Giese acceptor (Dha, 1), different from Karady–Beckwith alkene, highly stereoselective at room temperature, providing





Scheme 7. Synthetic Procedure to Obtain the UAA Hsc(SePh) 4k from Ser Derivative 7



clean reactions and high yields of 1,4-adducts 3c-n. The subsequent deprotection of these derivatives allows for the synthesis of a variety of UAA 4. Apart from these synthetic advantages, Dha 1 offers the attractive feature that its carboxylic acid group is efficiently protected and activated in the form of oxazolidine-5-one, which allows coupling with amino acids to obtain peptides. Thus, as a synthetic application of 1,4-aducts 3, we coupled 3k with the α -amino ester hydrochloride derived from Phe in the presence of sodium 2ethylhexanoate as a base to give dipeptide 5k in a good yield (74%, Scheme 6). The acidic hydrolysis of 5k with 4 M HCl at 60 °C and subsequent purification by semipreparative HPLC gave enantiopure L-Hsc(SePh)-L-Phe (6k) in high yields (95 and 70% global yield for two steps, Scheme 5).

In addition, to demonstrate the feasibility of this synthetic process to afford unnatural amino acids, we have scaled up the synthesis of the UAA *Se*-phenylhomoselenocysteine **4k**, including the synthetic procedure to obtain the chiral substrate

Dha 1 (on a gram scale) from readily available raw materials (Scheme 7 and SI).

Thus, following our procedure previously published,^{11a} starting from 11.4 g of (R)-N-Boc-serine methyl ester (N-Boc-D-Ser-OMe, 7) and 2,2,3,3-tetramethoxybutane (TMB, 8), the corresponding bicyclic N,O-acetal 2b was obtained in a 75% yield (9.4 g). This compound 2b (2.8 g) was transformed with a 95% yield into the first-generation chiral Dha 9 (2.6 g). The second-generation Dha 1 (1.4 g) was obtained from Dha 9 (2.1 g) through basic hydrolysis followed by an internal coupling (lactonization).^{10a} The photoredox catalytic 1,4conjugate addition of PhSeCH₂CO₂H (2k) to Dha 1 (200 mg) gave the adduct 3k (205 mg, 57%) with somewhat less yield than that obtained with smaller amounts. Next, an amount of 3k (45 mg) was readily hydrolyzed to the UAA Hsc(SePh) 4k (27 mg, 93%). Finally, our methodology allows to obtain Hsc(SePh) from a Ser derivative using six steps with an overall yield of 69%. This method competes with several published

methods to obtain Se-substituted homoselenocysteine derivatives.¹⁹ For instance, from *tert*-butyl 2-((diphenylmethylene)amino)acetate, a glycine derivative, and using five steps, N-Boc-Se-(ortho-nitrophenyl)selenohomocysteine tert-butyl ester was obtained in an overall yield of 50%. In the same way, free Se-(methyl)selenohomocysteine (also known as selenomethionine) was obtained using eight steps in an overall yield of 32%. In both cases, the stereoselectivity was introduced via a chiral alkylation of a glycine derivative using a chiral cinchonaderived phase-transfer catalyst.^{19a,b} Moreover, selenomethionine has been used to synthesize Se-(para-methoxtbenzyl)homoselenocysteine via homoselenocystine in an overall yield of 62% (20% overall yield from the above-cited glycine derivative and using 10 steps).^{19c} In addition, (S)-Se-(phenyl)selenohomocysteine was synthesized from (S)-methionine using seven steps in an overall yield of 34% and all of them involved interconversion of functional groups.^{19d}

In conclusion, this work describes the totally chemo- and stereoselective 1,4-conjugate additions of different anionic and radical C-nucleophiles to chiral bicyclic dehydroalanine Dha 1. This methodology allows the synthesis of enantiopure unnatural amino acids (UAAs) with structural diversity. Besides, both the diastereoselective incorporation of β carbon-sidechain and the selective α -deuteration occur concomitantly giving access to enantioenriched α -deuterated UAAs. This procedure not only utilizes the photoredox methodology based on visible light to generate enantiopure UAA but offers additional synthetic advantages. Thus, the oxazolidine-5-one skeleton of these 1,4-adducts gives access to peptides incorporating different UAAs. In summary, readily available starting materials, mild conditions, metal-free photocatalysts, functional group tolerance, and high yields and stereoselectivities make this strategy an appealing method for the synthesis of enantiomerically pure UAAs.

EXPERIMENTAL SECTION

General and Experimental Methods. Commercial reagents were used without further purification. Analytical thin-layer chromatography (TLC) was performed on Macherey-Nagel precoated aluminum sheets with a 0.20 mm thickness of silica gel 60 with the fluorescent indicator UV254. TLC plates were visualized with UV light and by staining with a potassium permanganate solution (0.75 g of KMnO₄, 5 g of K₂CO₃, and 0.63 mL of 10% NaOH in 100 mL of water) or a ninhydrin solution (1.5 g of ninhydrin in 100 mL of nbutanol and 3.0 mL of acetic acid). Column chromatography was performed on silica gel (230-400 mesh). ¹H and ¹³C{¹H} NMR spectra were measured with a 300 or 400 MHz spectrometer with TMS as the internal standard. Multiplicities are quoted as singlet (s), broad singlet (br s), doublet (d), doublet of doublets (dd), triplet (t), or multiplet (m). Spectra were assigned using COSY and HSQC experiments. The results of these experiments were processed with MestreNova software. High-resolution electrospray mass (ESI) spectra were recorded on a microTOF spectrometer; accurate mass measurements were achieved by using sodium formate as an external reference.

C-Michael Addition on Dha 1 Followed by Hydrolysis to Obtain Glutamic Acid Derivatives. Dha 1 was obtained in a gram scale from N-Boc-D-Ser-OMe 7 following the published procedure.^{10a} Compound 2a, carboxylic acids 2c-j, and 2l-o are commercially available. Bicyclic compound 2b,^{11a} carboxylic acid 2k,²⁰ and Boc-D-Ser-OMe²¹ 7 were synthesized following the procedures described in the literature. The NMR spectra of these compounds were included in the SI.

Diethyl-2-(((3S,7S,7aR)-7-methoxy-7,7a-dimethyl-2,5-dioxotetrahydro-5H-oxazolo[4,3-b]oxazol-3-yl)methyl)malonate (3a). Chiral bicyclic Dha 1 (21 mg, 0.1 mmol, 1.0 equiv) and diethyl

malonate 2a (18 µL, 0.11 mmol, 1.1 equiv) were dissolved, at room temperature, in anhydrous THF (final concentration 0.1 M) in a Schlenk under an Ar atmosphere. Then, a 1 M solution of LHMDS in THF (0.2 mL, 2.0 equiv) was added with a syringe. The reaction was monitored by TLC (7:3, hexanes/ethyl acetate. R_f (Dha) = 0.75) and, once completed (5 min), the solution was dried under vacuum. The crude mixture was purified by column chromatography on silica gel (hexanes/ethyl acetate, 7:3) to afford compound 3a as a sticky foam (30 mg, 0.08 mmol, 81% yield). $[\alpha]_{\rm D}^{20}$ +83.7 (c 1.0, CHCl₃). HRMS (ESI) m/z: $[M + Na]^+$ calcd for C₁₆H₂₃NO₉Na 396.1265; Found 396.1268. ¹H NMR (CDCl₃, 400 MHz): δ 4.43 (dd, 1H, J = 11.6, 5.2 Hz, $H^{3\alpha}$), 4.16–4.28 (m, 4H, 2CH₂^b), 3.66 (dd, 1H, J = 8.3, 6.0 Hz, H^a), 3.48 (s, 3H, OMe⁷), 2.66 (ddd, 1H, J = 14.0, 8.3, 5.2 Hz, H^{β}), 2.26 (ddd, 1H, J = 14.0, 11.6, 6.0 Hz, H^{β}), 1.65 (s, 3H, CH_3^{7a}), 1.61 (s, 3H, CH₃⁷), 1.24–1.32 (m, 6H, 2CH₂^c). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 171.1, 168.6, 168.0, 159.2 (4CO), 108.3 (C⁷), 101.7 (C^{7a}) , 62.2 (C^b), 62.1 (C^b), 59.0 (C^{3a}), 51.7 (OMe⁷), 48.9 (C^a), 30.2 (C^{β}), 22.0 (CH₃^{7a}), 16.6 (CH₃⁷), 14.1 (C^c), 14.1 (C^c).

Methyl(3R,3'S,7S,7aR,7'S,7'aR)-7,7'-dimethoxy-7,7a,7',7'a-tetramethyl-2',5,5' trioxohe-xahydro-5H,5'H-[3,3'-bioxazolo[4,3-b]oxazole]-3(2H)-carboxylate (3b). Chiral bicyclic Dha 1 (21 mg, 0.1 mmol, 1.0 equiv) and chiral bicyclic serine derivative 2b (24 mg, 0.1 mmol, 1.0 equiv) were dissolved in anhydrous THF (final concentration 0.1 M) in a Schlenk under Ar atmosphere. Then, the mixture was cooled down to -78 °C and a 1 M solution of LHMDS in THF (0.2 mL, 2.0 equiv) was added with a syringe. The reaction was monitored by TLC (7:3, hexanes/ethyl acetate. R_f (**Dha**) = 0.75) and, once completed (5 min), the solution was dried under vacuum. The crude mixture was purified by column chromatography on silica gel (hexanes/ethyl acetate, 7:3) to afford compound 3b as a sticky foam, but with time and solvents, monocrystals were formed. (32 mg, 0.07 mmol, 70% yield). $[\alpha]_{D}^{20}$ +49.4 (c 1.0, CHCl₃). HRMS (ESI) m/z: $[M + Na]^+$ calcd for $C_{19}H_{26}N_2O_{11}Na$ 481.1429; Found 481.1411. ¹H NMR (CDCl₃, 400 MHz): δ 5.00 (d, 1H, J = 9.2 Hz, $H^{2'}$), 4.24 (dd, 1H, J = 11.0, 3.7 Hz, $H^{3\alpha}$), 4.16 (d, 1H, J = 9.2 Hz, H²'), 3.79 (s, 3H, CO₂CH₃), 3.48 (s, 3H, OMe⁷), 3.45 (s, 3H, OMe^{77}), 3.33 (dd, 1H, J = 14.7, 11.0 Hz, H^{β}), 2.49 (dd, 1H, J = 14.7, 3.7 Hz, H^{β}), 1.66 (s, 3H, CH_3^{7a}), 1.62 (s, 3H, CH_3^{7}), 1.56 (s, 3H, $CH_3^{7\prime}$), 1.36 (s, 3H, $CH_3^{7\prime a}$). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 170.9, 170.5, 159.0, 154.7 (4CO), 107.8, 107.7, 102.5, 102.3 (4C^{7,7/,7a,7/a}), 72.8 (C²), 67.2 (C³), 57.8 (C^{3 α}), 53.4 (CO₂<u>C</u>H₃), 51.7 (OMe⁷), 51.7 (OMe⁷), 34.2 (C^{β}), 21.5 (CH₃^{7a}), 18.6 (C⁷),

16.6 (CH₃⁷), 16.2 (CH₃⁷). Diethyl-2-(((3S,7S,7aR)-7-methoxy-7,7a-dimethyl-2,5-dioxotetrahydro-5H-oxazolo[4,3-b]oxazol-3-yl-3-d)methyl)malonate (3a-D). Chiral bicyclic Dha 1 (21 mg, 0.1 mmol, 1.0 equiv) and diethyl malonate 2a (18 μ L, 0.11 mmol, 1.1 equiv) were dissolved, at room temperature, in a 9:1 mixture of 2-propanol-OD (ⁱPrOD) and anhydrous CH₂Cl₂ (final concentration 0.1 M) in a Schlenk under an Ar atmosphere. Then, a 1 M solution of LHMDS in THF (0.2 mL, 2.0 equiv) was added with a syringe. The reaction was monitored by TLC (7:3, hexanes/ethyl acetate. R_f (Dha) = 0.75) and, once completed (5 min), the solution was dried under vacuum. The crude mixture was purified by column chromatography on silica gel (hexanes/ethyl acetate, 7:3) to afford compound 3a-D as a sticky foam (27 mg, 0.07 mmol, 73% yield, 94% D). $[a]_D^{20}$ +85.4 (c 1.0, CHCl₃). HRMS (ESI) m/z: $[M + H]^+$ calcd for $C_{16}H_{23}DNO_9$ 375.1508; Found 375.1504. ¹H NMR (CDCl₃, 400 MHz): δ 4.43 (dd, 0.06H, J = 11.6, 5.2 Hz, $H^{3\alpha}$), 4.16–4.28 (m, 4H, 2CH₂^b), 3.66 (dd, 1H, J = 8.3, 5.9 Hz, H^a), 3.48 (s, 3H, OMe⁷), 2.66 (dd, 1H, J = 14.4, 8.3 Hz, H^{β}), 2.25 (dd, 1H, J = 14.4, 5.9 Hz, H^{β}), 1.65 (s, 3H, CH_3^{7a}), 1.61 (s, 3H, CH_3^7), 1.24–1.31 (m, 6H, $2CH_2^c$). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 171.1, 168.6, 168.0, 159.2 (4CO), 108.3 (C^{7}) , 101.7 (C^{7a}) , 62.2 (C^{b}) , 62.1 (C^{b}) , 58.8 $(t, J= 21.6 \text{ Hz}, C^{3\alpha})$, $51.7 (OMe^7)$, $48.8 (C^a)$, $30.1 (C^{\beta})$, $22.0 (CH_3^{7a})$, $16.6 (CH_3^{7})$, 14.1(C^c), 14.1 (C^c).

General Procedure for Hydrolysis of Michael Adducts. Compound 3a (15 mg, 0.04 mmol), 3a-D (15 mg, 0.04 mmol), or 3b (15 mg, 0.03 mmol) was suspended in a 6 M HCl aqueous solution (3.0 mL), and the reaction mixture was stirred at 60 °C in an oil bath for 16 h. The solvent was then removed under vacuum, the crude mixture was dissolved in water (5 mL), washed with ethyl acetate (5 mL), and purified by solid phase extraction in a C18 cartridge to afford 4a (5.5 mg, 0.04 mmol, 93% yield), 4a-D (5.7 mg, 0.04 mmol, 96% yield, 88% D), or 4b (6 mg, 0.03 mmol, 95% yield).

ι-Glutamic Acid Hydrochloride (4a). Following the general procedure for hydrolysis. Yield after SPE cartridge: 5.5 mg, 93%. White solid. $[\alpha]_D^{20}$ +32.7 (c 1.0, 6 M HCl). HRMS (ESI) m/z: $[M + H]^+$ calcd for $C_5H_{10}NO_4$ 148.0604; Found 148.0606. ¹H NMR (D₂O, 400 MHz): δ 4.01 (t, 1H, J = 6.5 Hz, H^{α}), 2.57–2.62 (m, 2H, H^{γ}), 2.11–2.25 (m, 2H, H^{β}). ¹³C{¹H} NMR (D₂O, 100 MHz): δ 176.4, 172.2 (2CO), 52.6 (H^{α}), 29.5 (C^{γ}), 25.0 (C^{β}).

L-*Glutamic-2-d Acid Hydrochloride* (**4***a*–*D*). Following the general procedure for hydrolysis. Yield after SPE cartridge: 5.7 mg, 96%. White solid. $[\alpha]_D^{20}$ +30.2 (c 1.0, 6 M HCl). HRMS (ESI) *m/z*: $[M - H]^-$ calcd for C₅H₇DNO₄ 147.0522; Found 147.0519. ¹H NMR (D₂O, 400 MHz): δ 4.08 (t, 1H, *J* = 6.6 Hz, 0.12H^{α}), 2.60–2.66 (m, 2H, H^{γ}), 2.15–2.28 (m, 2H, H^{β}). ¹³C{¹H} NMR (D₂O, 100 MHz): δ 176.4, 172.0 (2CO), 52.1 (t, *J* = 22.5 Hz, H^{α}), 29.5 (C^{γ}), 24.9 (C^{β}).

(2*R*,4*S*)-2,4-Diamino-2-(hydroxymethyl)pentanedioic Acid Dihydrochloride (4b). Following the general procedure for hydrolysis. Yield after SPE cartridge: 6.0 mg, 95%. White solid. $[\alpha]_D^{20}$ +10.6 (c 1.0, 6 M HCl). HRMS (ESI) m/z: $[M + H]^+$ calcd for C₆H₁₃N₂O₅ 193.0819; Found 193.0822. ¹H NMR (D₂O, 400 MHz): δ 4.31 (t, 1H, *J* = 9.4 Hz, H^{α}), 3.87 (d, 1H, *J* = 11.6 Hz, H^{δ}), 3.82 (d, 1H, *J* = 11.6 Hz, H^{δ}), 2.81 (dd, 1H, *J* = 13.8, 9.4 Hz, H^{β}), 2.39 (dd, 1H, *J* = 13.8, 9.4 Hz, H^{β}). ¹³C{¹H} NMR (D₂O, 100 MHz): δ 174.5, 172.4 (2CO), 65.5 (C^{γ}), 62.7 (C^{δ}), 50.0 (C^{α}), 32.0 (C^{β}).

Photoredox Catalytic 1,4-Additions to Chiral Dha 1 Followed by Hydrolysis to Obtain Carbon- β -Substituted UAAs. General Procedure for Photoredox Catalytic 1,4-Additions. Chiral bicyclic Dha 1 (21 mg, 0.1 mmol, 1.0 equiv), the corresponding carboxylic acid 2c-n (0.12 mmol, 1.2 equiv), Cs₂CO₃ (39 mg, 0.15 mmol, 1.5 equiv), and 4CzIPN (4 mg, 0.005 mmol, 0.05 equiv) were added in sample vials. The tube was evacuated and back-filled with N2 (three times). Then, anhydrous DMF (1 mL, final concentration 0.1 M) was added using a syringe. The solution was then stirred at room temperature under the irradiation of Blue LEDs for 2-16 h. Once completed, 1 mL of water was added and extracted with ethyl acetate. The combined organic layer was dried over anhydrous Na2SO4, filtered, and evaporated under vacuum. The crude mixture was purified by column chromatography (hexanes/ethyl acetate) on silica gel to afford desired products. Light-promoted reactions have been carried out in a SynLED Parallel Photoreactor (available from Sigma-Aldrich). Bottom-lit LEDs (465-470 nm) across a 4 × 4 reaction block array provide consistent light intensity (130-140 lm) and an angle (45°) . A built-in cooling fan provides consistent temperature to each parallel reaction. Uses 1-2 dram scintillation vials or microwave vials (O.D. of 1.7 cm or less). A power supply is a wall plug power supply 700 mA 12 W. Wheaton sample vials (clear borosilicate glass vial).

Procedure to Scale Up the Photoredox Catalytic 1,4-Additions. Chiral bicyclic Dha 1 (200 mg, 0.93 mmol, 1.0 equiv), 2-(phenylselanyl)acetic acid 2k (240 mg, 1.12 mmol, 1.2 equiv), Cs₂CO₃ (371 mg, 1.40 mmol, 1.5 equiv), and 4CzIPN (38 mg, 0.046 mmol, 0.05 equiv) were added in a 50 mL flask. The vessel was evacuated and refilled with N_2 (×3). Then, anhydrous DMF (10 mL, final concentration 0.1 M) was added using a syringe. The solution was then stirred at room temperature under the irradiation of Blue LEDs for 16 h. Once completed, 10 mL of water was added and extracted with ethyl acetate. The combined organic layer was dried over anhydrous Na₂SO₄ and dried under vacuum. The crude mixture was purified by column chromatography (hexanes/ethyl acetate, 7:3) on silica gel to afford 3k (205 mg, 0.53 mmol, 57%). Light-promoted reactions on a larger scale have been carried out by irradiating with the blue light of an RGB LED of 50 W. Ce RoHS EMC IP65 50 W at 15 cm from the flask on the stirring plate in a photochemical cabinet.

General Procedure for Deuterated Compounds. Chiral bicyclic Dha 1 (21 mg, 0.1 mmol, 1.0 equiv), deuterated carboxylic acids (0.12 mmol, 1.2 equiv), Cs₂CO₃ (39 mg, 0.15 mmol, 1.5 equiv),

and 4CzIPN (4 mg, 0.005 mmol, 0.05 equiv) were added in sample vials. The tube was evacuated and back-filled with N₂ (three times). Then, anhydrous DMF (1 mL, final concentration 0.1 M) and D₂O (50 μ L) were added using a syringe. The solution was then stirred at room temperature under the irradiation of Blue LEDs (SynLED parallel photoreactor) for 2–16 h. Once completed, 1 mL of D₂O was added and extracted with ethyl acetate. The combined organic layer was dried over anhydrous Na₂SO₄, filtered, and evaporated under vacuum. The crude mixture was purified by column chromatography (hexanes/ethyl acetate) on silica gel to afford desired products.

General Procedure for Hydrolysis of Adducts. Compounds were suspended in a 4 M HCl aqueous solution and the reaction mixture was stirred at 60 $^{\circ}$ C in an oil bath for 16 h. The solvent was then removed under vacuum, the crude mixture was dissolved in water (5 mL), washed with ethyl acetate (5 mL), and purified by solid phase extraction in a C18 cartridge to afford desired products.

Aminolysis of Adduct 3k with HCl-Phe-OBn. Compound 3k (64 mg, 0.16 mmol), the corresponding amino ester hydrochloride (H-Phe-OBn·HCl, 73 mg, 0.25 mmol, 1.5 equiv), and sodium 2-ethylhexanoate (69 mg, 0.42 mmol, 2.5 equiv) were charged in an oven-dried Schlenk flask and subjected to a vacuum/N₂ cycle (×3) to remove possible moisture. Under a N₂ atmosphere, dry THF (8 mL, 50 mL mmol⁻¹) was added to the flask by a syringe. The solution was stirred at room temperature for 24 h. After that time, brine and ethyl acetate were added to the solution. Layers were separated and the aqueous layer was back-extracted with more ethyl acetate. The crude mixture was purified by column chromatography (hexanes/ethyl acetate 7:3) on silica gel to afford the desired product Sk.

tert-Butyl-(2-((35,75,7aR)-7-methoxy-7,7a-dimethyl-2,5-dioxotetrahydro-5H-oxazolo[4,3-b]oxazol-3-yl)ethyl)carbamate (**3c**). Following the general procedure. Yield after column chromatography (hexanes/ethyl acetate, 8:2): 30 mg, 88%. White solid. Mp: 116–119. $[\alpha]_{\rm D}^{20}$ +34.5 (c 1.0, CHCl₃). HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₁₅H₂₄N₂O₇ 345.1656; Found 345.1652. ¹H NMR (CDCl₃, 400 MHz): δ 5.13 (br s, 1H, H^{NH}), 4.37 (dd, 1H, *J* = 12.0, 4.2 Hz, H^{3α}), 3.56–3.60 (m, 1H, CH₂^γ), 3.51 (s, 3H, OMe⁷), 3.15–3.23 (m, 1H, CH₂^γ), 2.22–2.29 (m, 1H, H^β), 1.76–1.84 (m, 1H, H^β), 1.63 (s, 6H, CH₃^{7a}, CH₃⁷), 1.44 (s, 9H, NHBoc). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 172.0, 159.6, 156.0 (3CO), 108.9 (C⁷), 101.3 (C^{7a}), 79.7 (<u>C</u>(CH₃)₃), 58.7 (C^{3α}), 51.9 (OMe⁷), 37.6 (C^γ), 31.4 (C^β), 28.5 (C(<u>C</u>H₃)₃), 22.4 (CH₃^{7a}), 16.8 (CH₃⁷).

tert-Butyl-(2-((35,75,7*a*R)-7-methoxy-7,7*a*-dimethyl-2,5-dioxotetrahydro-5*H*-oxazolo[4,3-b]oxazol-3-yl-3-d)ethyl)carbamate (3*c*-*D*). Following the general procedure for deuterated compounds. Yield after column chromatography (hexanes/ethyl acetate, 8:2): 28 mg, 82% [93% deuterated]. White solid. Mp: 118–118. $[\alpha]_D^{20}$ +36.4 (c 1.0, CHCl₃). HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₁₅H₂₃DN₂O₇Na 368.1544; Found 368.1549. ¹H NMR (CDCl₃, 400 MHz): δ 5.12 (br s, 1H, H^{NH}), 4.37 (dd, 0.07H, *J* = 11.4, 4.2 Hz, H^{3α}), 3.56–3.60 (m, 1H, CH₂^γ), 3.51 (s, 3H, OMe⁷), 3.13–3.25 (m, 1H, CH₂^γ), 2.20–2.29 (m, 1H, H^β), 1.76–1.84 (m, 1H, H^β), 1.63 (s, 6H, CH₃^{7a}, CH₃⁷), 1.44 (s, 9H, NHBoc). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 172.0, 159.6, 155.9 (3CO), 108.9 (C⁷), 101.3 (C^{7a}), 79.7 (<u>C</u>(CH₃)₃), 51.9 (OMe⁷), 37.5 (C^γ), 31.2 (C^β), 28.5 (C(<u>C</u>H₃)₃), 22.4 (CH₃^{7a}), 16.8 (CH₃⁷). *C^{3α} is not observed.

(35,75,7*α*)-7-*Methoxy*-7,7*a*-*dimethyl*-3-*phenethyldihydro*-5*H*-*oxazolo*[4,3-*b*]*oxazole*-2,5(3*H*)-*dione* (**3d**). Following the general procedure. Yield after column chromatography (hexanes/ethyl acetate, 8:2): 22 mg, 73%. Light yellow solid. Mp: 52-55. $[\alpha]_D^{20}$ +52.2 (c 1.0, CHCl₃). HRMS (ESI) *m/z*: $[M + Na]^+$ calcd for C₁₆H₁₉NNaO₅ 328.1155; Found 328.1150. ¹H NMR (CDCl₃, 400 MHz): δ 7.20–7.34 (m, 5H, H^{Ar}), 4.32 (dd, 1H, *J* = 10.9, 4.8 Hz, H^{3α}), 3.51 (s, 3H, OMe⁷), 2.82–2.97 (m, 2H, CH₂^γ), 2.27–2.36 (m, 1H, H^β), 1.95–2.06 (m, 1H, H^β), 1.66 (s, 3H, CH₃^{7a}), 1.63 (s, 3H, CH₃⁷). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 172.1, 159.5 (2CO), 140.0 (C*^{Ar}), 128.8 (4C^{Ar}), 126.6 (C^{Ar}), 108.2 (C⁷), 101.6 (C^{7a}), 60.5 (C^{3α}), 51.7 (OMe⁷), 33.7 (C^β), 32.6 (C^γ), 22.2 (CH₃^{7a}), 16.7 (CH₃⁷).

(3S,7S,7aR)-3-(Cyclohexylmethyl)-7-methoxy-7,7a-dimethyldihydro-5H-oxazolo[4,3-b]oxazole-2,5(3H)-dione (3e). Following the general procedure. Yield after column chromatography (hexanes/ ethyl acetate, 8:2): 25 mg, 85%. Light yellow solid. Mp: 60–63. $[\alpha]_{\rm D}^{20}$ +68.5 (c 1.0, CHCl₃). HRMS (ESI) m/z: $[M + Na]^+$ calcd for C₁₅H₂₃NNaO₅ 320.1468; Found 320.1474. ¹H NMR (CDCl₃, 400 MHz): δ 4.41 (dd, 1H, J = 11.1, 4.3 Hz, H^{3 α}), 3.50 (s, 3H, OMe⁷), 1.96–2.03 (m, 1H, 1CH₂^{cyclo}), 1.68–1.86 (m, 5H, 4CH₂^{cyclo}, 1H^{β}), 1.64 (s, 3H, CH₃^{7a}), 1.62 (s, 3H, CH₃⁷), 1.54–1.65 (m, 2H, CH^{cyclo}, 1H^{β}), 1.14–1.30 (m, 3H, 3CH₂^{cyclo}), 0.56–1.09 (m, 2H, 3CH₂^{cyclo}). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 173.0, 159.6 (2CO), 107.9 (C⁷), 101.6 (C^{7a}), 59.2 (C^{3 α}), 51.6 (OMe⁷), 38.9 (C^{β}), 34.9 (CH^{cyclo}), 33.6 (CH₂^{cyclo}), 31.8 (CH₂^{cyclo}), 26.5 (CH₂^{cyclo}), 26.3 (CH₂^{cyclo}), 26.0 (CH₂^{cyclo}), 22.1 (CH₃^{7a}), 16.6 (CH₃⁷).

(35,75,7*aR*)-7-*Methoxy-7,7a-dimethyl-3-((1-methylcyclohexyl)-methyl)dihydro-5H-oxazolo[4,3-b]oxazole-2,5(3H)-dione (3f). Following the general procedure. Yield after column chromatography (hexanes/ethyl acetate, 8:2): 25 mg, 82%. Light yellow solid. Mp: 76–79. [\alpha]_D^{20} +67.1 (c 1.0, CHCl₃). HRMS (ESI) <i>m/z*: [M + Na]⁺ calcd for C₁₆H₂₅NNaO₅ 334.1625; Found 334.1620. ¹H NMR (CDCl₃, 400 MHz): δ 4.45 (dd, 1H, *J* = 10.9, 2.5 Hz, H^{3α}), 3.49 (s, 3H, OMe⁷), 1.88 (dd, 1H, *J* = 14.5, 2.5 Hz, H^β), 1.72 (dd, 1H, *J* = 14.5, 10.9 Hz, H^β), 1.66 (s, 3H, CH₃^{7a}), 1.62 (s, 3H, CH₃⁻⁷), 1.38–1.52 (m, 10H, H^{cyclo}), 1.07 (s, 3H, CH₃^{cyclo}). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 173.7, 159.4 (2CO), 107.6 (C⁷), 101.9 (C^{7a}), 58.1 (C^{3α}), 51.6 (OMe⁷), 43.2 (C^β), 37.7 (CH₂^{cyclo}), 37.6 (CH₂^{cyclo}), 33.6 (C*^{cyclo}), 26.3 (CH₂^{cyclo}), 24.4 (CH₃^{cyclo}), 22.0 (2CH₂^{cyclo}), 22.0 (CH₃^{-7a}), 16.6 (CH₃^{-7a}).

(35,75,7*a*R)-7-*M*ethoxy-7,7*a*-dimethyl-3-neopentyldihydro-5*H*-oxazolo[4,3-b]oxazole-2,5(3*H*)-dione (**3g**). Following the general procedure. Yield after column chromatography (hexanes/ethyl acetate, 8:2): 23 mg, 86%. Yellow solid. Mp: 91–93. $[\alpha]_D^{20}$ +79.5 (c 1.0, CHCl₃). HRMS (ESI) *m*/*z*: [M + Na]⁺ calcd for C₁₃H₂₁NNaO₅ 294.1312; Found 294.1304. ¹H NMR (CDCl₃, 400 MHz): δ 4.42 (dd, 1H, *J* = 11.1, 2.6 Hz, H^{3α}), 3.49 (s, 3H, OMe⁷), 1.87 (dd, 1H, *J* = 14.5, 2.6 Hz, H^β), 1.63–1.68 (m, 1H, H^β), 1.65 (s, 3H, CH₃^{7a}), 1.62 (s, 3H, CH₃⁷), 1.06 (s, 9H, (CH₃)₃). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 173.5, 159.4 (2CO), 107.6 (C⁷), 101.8 (C^{7a}), 58.8 (C^{3α}), 51.6 (OMe⁷), 44.7 (C^β), 31.2 (<u>C</u>(CH₃)₃), 29.3 (3C(<u>C</u>H₃)₃), 22.0 (CH₃^{7a}), 1.66 (CH₃⁷).

(35,75,7*a*R)-3-*i*so-Butyl-7-*m*ethoxy-7,7*a*-dimethyldihydro-5*H*oxazolo[4,3-*b*]oxazole-2,5(3*H*)-dione (3*h*). Following the general procedure. Yield after column chromatography (hexanes/ethyl acetate, 8:2): 20 mg, 83%. Sticky foam. $[\alpha]_D^{20}$ +52.5 (c 1.0, CHCl₃). HRMS (ESI) *m*/*z*: [M +Na]⁺ calcd for C₁₂H₁₉NNaO₅ 280.1155; Found 280.1146. ¹H NMR (CDCl₃, 400 MHz): δ 4.37 (dd, 1H, *J* = 11.5, 4.5 Hz, H^{3α}), 3.50 (s, 3H, OMe⁷), 1.88–1.98 (m, 1H, C<u>H</u>(CH₃)₂), 1.79 (ddd, 1H, *J* = 13.4, 8.8, 4.5 Hz, H^β), 1.64–1.69 (m, 1H, H^β), 1.64 (s, 3H, CH₃⁻⁷), 1.62 (s, 3H, CH₃⁻⁷), 1.06 (d, 3H, *J* = 6.5, 1CH(C<u>H₃)₂), 1.03 (d, 3H, *J* = 6.7, 1CH(C<u>H₃)₂). ¹³C</u>{¹H} NMR (CDCl₃, 100 MHz): δ 172.8, 159.6 (2CO), 107.9 (C⁷), 101.6 (C^{7a}), 59.7 (C^{3α}), 51.7 (OMe⁷), 40.2 (C^β), 25.8 (<u>C</u>H(CH₃)₂), 22.9 (1CH(<u>C</u>H₃)₂), 22.1 (CH₃^{7a}), 21.3 (1CH(<u>C</u>H₃)₂), 16.6 (CH₃⁷).</u>

(35,75, 7*a*R)-7-Methoxy-7,7*a*-dimethyl-3-(2-phenoxyethyl)dihydro-5H-oxazolo[4,3-b]oxazole-2,5(3H)-dione (3i). Following the general procedure. Yield after column chromatography (hexanes/ethyl acetate, 8:2): 27 mg, 85%. Sticky foam. $[\alpha]_D^{20}$ +32.2 (c 1.0, CHCl₃). HRMS (ESI) *m/z*: [M + Na]⁺ calcd for C₁₆H₁₉NNaO₆ 344.1105; Found 344.1098. ¹H NMR (CDCl₃, 400 MHz): δ 7.28-7.31 (m, 2H, CH^{At}), 6.92-7.00 (m, 3H, CH^{At}), 4.61 (dd, 1H, *J* = 10.4, 5.0 Hz, H^{3α}), 4.15-4.26 (m, 2H, CH₂^γ), 3.50 (s, 3H, OMe⁷), 2.44-2.54 (m, 1H, H^β), 2.12-2.21 (m, 1H, H^β), 1.66 (s, 3H, CH₃^{7a}), 1.66 (s, 3H, CH₃⁷). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 171.9, 159.2 (2CO), 129.7, 129.7, 121.4, 115.0, 115.0 (5C^{At}), 108.2 (C⁷), 101.6 (C^{7a}), 63.9 (C^γ), 57.9 (C^{3α}), 51.8 (OMe⁷), 31.7 (C^β), 29.9 (C^{*At}), 22.2 (CH₃^{7a}), 16.7 (CH₃⁷).

(35,75,7*a*R)-7-Methoxy-7,7*a*-dimethyl-3-(2-(phenylthio)ethyl)dihydro-5H-oxazolo[4,3-b]oxazole-2,5(3H)-dione (**3***j*). Following the general procedure. Yield after column chromatography (hexanes/ethyl acetate, 8:2): 27 mg, 81%. White solid. Mp: 108– 110. $[\alpha]_D^{20}$ +48.2 (c 1.0, CHCl₃). HRMS (ESI) *m*/*z*: [M + Na]⁺ calcd for C₁₆H₁₉NNaO₅S 360.0876; Found 360.0871. ¹H NMR (CDCl₃, 400 MHz): δ 7.13–7.3 (m, 5H, CH^{Ar}), 4.42 (dd, 1H, J = 10.8, 4.8 Hz, H^{3α}), 3.44 (s, 3H, OMe⁷), 3.05–3.14 (m, 1H, CH₂^γ), 2.95–3.04 (m, 1H, CH₂^γ), 2.13–2.23 (m, 1H, H^β), 1.83–1.93 (m, 1H, H^β), 1.55 (s, 3H, CH₃⁷), 1.50 (s, 3H, CH₃^{7a}).¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 171.6, 159.3 (2CO), 134.9 (C^{*Ar}), 130.6, 130.6, 129.3, 129.3, 127.0 (SC^{Ar}), 108.3 (C⁷), 101.6 (C^{7a}), 59.8 (C^{3α}), 51.8 (OMe⁷), 31.5 (C^β), 30.8 (C^γ), 22.1 (CH₃^{7a}), 16.7 (CH₃⁷).

(3S,7S,7aR)-7-Methoxy-7,7a-dimethyl-3-(2-(phenylselanyl)ethyl)dihydro-5H-oxazolo[4,3-b]oxazole-2,5(3H)-dione (3k). Following the general procedure. Yield after column chromatography (hexanes/ethyl acetate, 8:2): 33 mg, 87%. Sticky foam, but with time and solvents we got monocrystals. $[α]_D^{20}$ +41.2 (c 1.0, CHCl₃). HRMS (ESI) *m/z*: $[M + Na]^+$ calcd for C₁₆H₁₉NNaO₅Se 408.0321; Found 408.0320. ¹H NMR (CDCl₃, 400 MHz): δ 7.43–7.50 (m, 2H, CH^{Ar}), 7.16–7.22 (m, 3H, CH^{Ar}), 4.41 (dd, 1H, *J* = 10.9, 4.9 Hz, H^{3α}), 3.43 (s, 3H, OMe⁷), 3.01–3.08 (m, 1H, CH₂^γ), 2.89–2.97 (m, 1H, CH₂^γ), 2.17–2.28 (m, 1H, H^β), 1.88–1.99 (m, 1H, H^β), 1.54 (s, 3H, CH₃⁷), 1.47 (s, 3H, CH₃^{7a}). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 171.6, 159.4 (2CO), 128.9 (C*^{Ar}), 133.7, 133.7, 129.4, 129.4, 127.7, 115.0 (SC^{Ar}), 108.3 (C⁷), 101.5 (C^{7a}), 60.7 (C^{3α}), 51.8 (OMe⁷), 32.4 (C^β), 23.7 (C^γ), 22.1 (CH₃^{7a}), 16.7 (CH₃⁷). tert-Butyl-(1-(((3S,7S,7aR)-7-methoxy-7,7a-dimethyl-2,5-dioxo-

tert-Butyl-(1-(((35,75,7aR)-7-methoxy-7,7a-dimethyl-2,5-dioxotetrahydro-5H-oxazolo[4,3-b]oxazol-3-yl)methyl)cyclohexyl)carbamate (**3**]). Following the general procedure. Yield after column chromatography (hexanes/ethyl acetate, 8:2): 32 mg, 78%. Light yellow solid. Mp: 84–87. $[\alpha]_D^{20}$ +145.7 (c 1.0, CHCl₃). HRMS (ESI) m/z: $[M + Na]^+$ calcd for $C_{20}H_{32}N_2NaO_7$ 435.2101; Found 435.2102. ¹H NMR (CDCl₃, 400 MHz): δ 4.56 (bs, 1H, NHBoc), 4.41 (d, 1H, *J* = 11.2 Hz, H^{3α}), 3.48 (s, 3H, OMe⁷), 2.41–2.51 (m, 1H, H^β), 2.24– 2.36 (m, 1H, H^{cycle}), 1.97–2.09 (m, 2H, H^β, H^{cycle}), 1.64 (s, 3H, CH₃^{-7a}), 1.61 (s, 3H, CH₃⁻⁷), 1.53–1.64 (m, 2H, H^{cycle}), 1.34–1.50 (m, 5H, H^{cycle}), 1.40 (s, 9H, 1C(CH₃)₃), 1.22–1.29 (m, 1H, H^{cycle}). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 173.2, 159.4 (2CO), 154.5 (<u>C</u>(CH₃)₃), 108.0 (C⁷), 102.0 (C^{7a}), 57.2 (C^{3α}), 53.5 (<u>C</u>NHBoc), 51.5 (OMe⁷), 38.1 (C^β), 34.9 (2C^{cycle}), 28.1, 28.4, 28.5 (C(CH₃)₃), 25.8 (C^{cycle}), 21.9 (CH₃^{-7a}), 21.5 (C^{cycle}), 21.3 (C^{cycle}), 1.65 (CH₃⁻⁷).

tert-Butyl-(1-((3S,7S,7aR)-7-methoxy-7,7a-dimethyl-2,5-dioxotetrahydro-5H-oxazolo[4,3-b]oxazol-3-yl)-2-methylpropan-2-yl)carbamate (**3m**). Following the general procedure. Yield after column chromatography (hexanes/ethyl acetate, 8:2): 28 mg, 76%. Light yellow solid. Mp: 78–81. $[\alpha]_{D}^{20}$ +43.8 (c 1.0, CHCl₃). HRMS (ESI) *m*/z: $[M +Na]^+$ calcd for $C_{17}H_{28}N_2NaO_7$ 395.1789; Found 395.1793. ¹H NMR (CDCl₃, 400 MHz): δ 4.71 (br s, 1H, N<u>H</u>Boc), 4.37 (d, 1H, *J* = 11.5 Hz, H^{3α}), 3.48 (s, 3H, OMe⁷), 2.45–2.57 (m, 1H, H^{β}), 2.01–2.10 (m, 1H, H^{β}), 1.64 (s, 3H, CH₃^{-7a}), 1.62 (s, 3H, C(C<u>H</u>₃)₂). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 172.6, 159.1 (2CO), 154.2 (<u>C</u>(CH₃)₃), 107.7 (C⁷), 101.7 (C^{7a}), 57.8 (C^{3α}), 51.2 (OMe⁷), 38.1 (C^{β}), 28.2 (4C, 3C(<u>C</u>H₃)₃), 1CH(<u>C</u>H₃)₂), 27.6 (1CH(<u>C</u>H₃)₂), 21.6 (CH₃^{-7a}), 16.2 (CH₃⁻⁷).

(35,75,7aR)-3-(hex-5-yn-1-yl)-7-Methoxy-7,7a-dimethyldihydro-5H-oxazolo[4,3-b]oxazole-2,5(3H)-dione (**3n**). Following the general procedure. Yield after column chromatography (hexanes/ethyl acetate, 8:2): 16 mg, 57%. Light yellow oil. $[\alpha]_{\rm D}^{20}$ +67.2 (c 1.0, CHCl₃). HRMS (ESI) *m/z*: $[M + H]^+$ calcd for C₁₄H₂₀NO₅ 282.13360; Found 282.13428. ¹H NMR (CDCl₃, 400 MHz): δ 4.27 (dd, 1H, *J* = 9.7, 4.9 Hz, H^{3α}), 3.50 (s, 3H, OMe⁷), 2.20–2.26 (m, 2H, CH₂), 2.00–2.08 (m, 1H, 1H^β), 1.95–1.98 (m, 1H, CH^{alkyne}), 2.61–1.78 (m, 5H, 2CH₂, 1H^β), 1.64 (s, 3H, CH₃^{7a}), 1.62 (s, 3H, CH₃⁷). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 172.3, 159.5 (2CO), 108.2 (C⁷), 101.6 (C^{7a}), 83.9 (C^{alkyne}), 68.9 (CH^{alkyne}), 60.9 (C^{3α}), 51.7 (OMe⁷), 31.1 (C^β), 27.5 (CH₂), 25.6 (CH₂), 22.2 (CH₃^{7a}), 18.3 (CH₂), 16.7 (CH₃⁷).

(*S*)-2,4-Diaminobutanoic Acid Dihydrochloride (4c). Following the general procedure for hydrolysis. Yield: 93%. $[\alpha]_D^{20}$ +14.2 (c 1.0, 6 M HCl). HRMS (ESI) m/z: $[M - H]^-$ calcd for C₄H₉N₂O₂ 117.0670; Found 117.0668. ¹H NMR (D₂O, 400 MHz): δ 3.99 (t, 1H, *J* = 6.5 Hz, H^{α}), 3.14–3.30 (m, 2H, H^{γ}), 2.18–2.31 (m, 2H, H^{β}). ¹³C{¹H} NMR (D₂O, 100 MHz): δ 172.0 (CO), 51.4 (C^{α}), 36.2 (C^{γ}), 27.8 (C^{β}). (*S*)-2,4-Diaminobutanoic-2-*d* Acid Dihydrochloride (4*c*-*D*). Following the general procedure for hydrolysis. Yield: 85% [89% deuterated]. $[\alpha]_D^{20}$ +13.8 (c 1.0, 6 M HCl). HRMS (ESI) *m/z*: [M – H]⁺ calcd for C₄H₁₀DN₂O₂ 120.0883; Found 120.0877. ¹H NMR (D₂O, 400 MHz): δ 3.90-3.93 (m, 0.11H, H^α), 3.14-3.22 (m, 2H, H^γ), 2.17-2.20 (m, 2H, H^β). ¹³C{¹H} NMR (D₂O, 100 MHz): δ 173.0 (CO), 36.4 (C^γ), 27.9 (C^β). C^α is not observed.

(*S*)-2-*Amino-4-(phenylselanyl)butanoic Acid Hydrochloride (4k).* Following the general procedure for hydrolysis. Yield: 93% (27 mg). $[\alpha]_{D}^{20} - 2.3$ (c 1.0, 6 M HCl). HRMS (ESI) m/z: $[M + H]^+$ calcd for C₁₀H₁₄NO₂Se 260.01843; Found 260.01715. ¹H NMR (D₂O, 400 MHz): δ 7.55–7.60 (m, H, CH^{Ar}), 7.32–7.38 (m, H, CH^{Ar}), 3.68 (t, 1H, *J* = 6.3 Hz, H^a), 2.99 (t, 2H, *J* = 7.9 Hz, H^{γ}), 2.03–2.19 (m, 2H, H^{β}). ¹³C{¹H} NMR (D₂O, 100 MHz): δ 170.1 (CO), 132.4 (2C^{Ar}), 129.4 (3C^{Ar}), 129.1(C^{*År}), 54.9 (C^a), 32.1 (C^{β}), 22.0 (C^{γ}).

129.4 (3C^{Ar}), 129.1(C*^{Ar}), 54.9 (C^α), 32.1 (C^β), 22.0 (C^γ). Benzyl-((S)-2-((4R,5S)-4-hydroxy-5-methoxy-4,5-dimethyl-2-oxooxazolidin-3-yl)-4-(phenylselanyl)butanoyl)-L-phenylalaninate (5k). Following the general procedure for aminolysis with amino ester hydrochlorides. Yield after column chromatography (hexanes/ethyl acetate, 7:3): 78 mg, 74%. Sticky foam. $[\alpha]_D^{20}$ +18.4 (c 1.0, CHCl₃). HRMS (ESI) m/z: $[M + Na]^+$ calcd for $C_{32}H_{36}N_2NaO_7Se$ 663.1585; Found 663.1609. ¹H NMR (CDCl₃, 400 MHz): δ 7.38–7.42 (m, 2H, CH^{Ar}), 7.27-7.30 (m, 2H, CH^{Ar}), 7.20-7.24 (m, 2H, CH^{Ar}), 7.16-7.19 (m, 3H, CH^{Ar}), 7.11-7.16 (m, 3H, CH^{Ar}), 6.93-6.97 (m, 2H, CH^{Ar}), 6.82 (d, 1H, J = 7.9 Hz, NH), 5.08 (d, 1H, J = 12.0 Hz, $1CH_2^{OBn}$), 5.01 (d, 1H, J = 12.0 Hz, $1CH_2^{OBn}$), 4.81 (ddd, 1H, J = 7.9, 5.5, 5.5 Hz H^{α Phe}), 4.34 (dd, 1H, J = 9.5, 5.9 Hz, H^{3α}), 4.28 (br s, 1H, OH), 3.12 (s, 3H, OMe⁷), 3.01 (t, 2H, J = 5.5 Hz, $CH_2^{\beta Phe}$), 2.88-2.97 (m, 1H, CH₂^γ), 2.75-2.83 (m, 1H, CH₂^γ), 2.36-2.48 (m, 1H, H^{β}), 2.20–2.31 (m, 1H, H^{β}), 1.44 (s, 3H, CH_3^{7}), 1.36 (s, 3H, CH₃^{7a}). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 170.8, 170.8, 155.9 (2CO), 135.3, 135.1, 129.9 (3C*Ar), 133.2-127.3 (15CAr), 107.9 (C⁷), 91.0 (C^{7a}), 67.5 (CH₂^{OBn}), 56.5 (C^{3a}), 53.8 (C^{aPhe}), 50.6 (OMe⁷), 38.0 (C^{β Phe}), 29.6 (C^{β}), 24.9 (C^{γ}), 20.4 (CH₃^{7a}), 14.1 $(CH_3^7).$

((Š)-2-Amino-4-(phenylselanyl)butanoyl)-L-phenylalanine (**6k**). Following the general procedure for hydrolysis. Yield: 95%. $[\alpha]_D^{20}$ –12.3 (c 1.0, 6 M HCl). HRMS (ESI) m/z: $[M - H]^+$ calcd for $C_{19}H_{23}N_2O_3Se$ 407.0874; Found 407.0878. ¹H NMR (D₂O, 400 MHz): δ 7.20–7.60 (m, 10H, CH^{Ar}), 3.86 (dd, 1H, J = 7.9, 5.2 Hz, H^{aPhe}), 3.69 (t, 1H, J = 6.7 Hz, H^a), 3.16 (dd, 1H, J = 14.5, 5.2 Hz, 1H^{βPhe}), 3.00 (dd, 1H, J = 14.5, 7.9 Hz, 1H ^{βPhe}), 2.90 (t, 2H, J = 7.8 Hz, H^γ), 1.80–2.15 (m, 2H, H^β). ¹³C{¹H} NMR (D₂O, 100 MHz): δ 174.2, 174.2 (2CO), 135.1 (C*^{Phe}), 132.5 (2C^{Ar}), 132.2 (C*^{Se}), 129.4, 129.3, 129.2, 129.0 128.6, 128.4, 127.6, 127.5 (8C^{Ar}), 56.0 (C^{aPhe}), 54.6 (C^a), 36.4 (C^{βPhe}), 31.2 (C^β), 21.8 (C^γ).

2D NMR Experiments. Spectra were assigned using COSY and edited-HSQC experiments (blue color for CH_2 and red color for CH and CH_3 groups). NOESY experiments were recorded on a 400 MHz spectrometer at 298 K. The experiments were conducted using phasesensitive ge-2D-NOESY spectra. The number of scans used was 16, and the mixing time was 800 ms.

X-ray Diffraction Analysis. CIF file for compounds 3k and 3b is presented in the Supporting Information. The SHELXL97 program²² was used for the refinement of crystal structures, and hydrogen atoms were fitted at theoretical positions.

Quantum Mechanical calculations. Full geometry optimizations and transition structure (TS) searches were carried out with Gaussian 16^{23} using the M06-2X hybrid functional,²⁴ 6-31+G(d,p) basis set with ultrafine integration grids. Bulk solvent effects in either *N*,*N*-dimethylformamide (DMF) or tetrahydrofuran (THF) were considered implicitly through the IEF-PCM polarizable continuum model.²⁵ The possibility of different conformations was considered for all structures. All stationary points were characterized by a frequency analysis performed at the same level used in the geometry optimizations from which thermal corrections were obtained at 298.15 K. The quasiharmonic approximation reported by Truhlar et al. was used to replace the harmonic oscillator approximation for the calculation of the vibrational contribution to entropy.²⁶ Scaled frequencies were not considered. Mass-weighted intrinsic reaction coordinate (IRC) calculations were carried out by using the Hratchian and Schlegel algorithm²⁷ to ensure that the TSs indeed connected the appropriate reactants and products. Gibbs free energies (ΔG) were used for the discussion on the relative stabilities of the considered structures. The lowest-energy conformer for each calculated stationary point was considered in the discussion

ASSOCIATED CONTENT

Supporting Information

pubs.acs.org/joc

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.joc.2c01774.

Experimental procedures, characterization data, computational details, and copies of the NMR spectra (PDF) (PDF)

Accession Codes

CCDC 2173824–2173825 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

AUTHOR INFORMATION

Corresponding Author

Jesús M. Peregrina – Departamento de Química, Centro de Investigación en Síntesis Química, Universidad de La Rioja, 26006 Logroño, La Rioja, Spain; O orcid.org/0000-0003-3778-7065; Email: jesusmanuel.peregrina@unirioja.es

Authors

- Paula Oroz Departamento de Química, Centro de Investigación en Síntesis Química, Universidad de La Rioja, 26006 Logroño, La Rioja, Spain
- Claudio D. Navo Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain; orcid.org/0000-0003-0161-412X
- Alberto Avenoza Departamento de Química, Centro de Investigación en Síntesis Química, Universidad de La Rioja, 26006 Logroño, La Rioja, Spain
- Jesús H. Busto Departamento de Química, Centro de Investigación en Síntesis Química, Universidad de La Rioja, 26006 Logroño, La Rioja, Spain; Orcid.org/0000-0003-4403-4790
- Francisco Corzana Departamento de Química, Centro de Investigación en Síntesis Química, Universidad de La Rioja, 26006 Logroño, La Rioja, Spain; orcid.org/0000-0001-5597-8127
- Gonzalo Jiménez-Osés Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain; Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain; © orcid.org/0000-0003-0105-4337

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.joc.2c01774

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

The authors thank the Agencia Estatal Investigación of Spain (AEI; grants RTI2018-099592-B-C21 and RTI2018-099592-B-C22 projects) and the EU (Marie-Sklodowska Curie ITN, DIRNANO, grant agreement No. 956544). P.O. thanks Universidad de La Rioja for a grant.

DEDICATION

Dedicated to Prof. Joan Bosch on the occasion of his 75th birthday.

REFERENCES

(1) (a) Blaskovich, M. A. T. Unusual amino acids in medicinal chemistry. J. Med. Chem. 2016, 59, 10807. (b) Walsh, C. T.; O'Brien, R. V.; Khosla, C. Nonproteinogenic amino acid building blocks for nonribosomal peptide and hybrid polyketide scaffolds. Angew. Chem., Int. Ed. 2013, 52, 7098. (c) Walsh, C. T.; O'Brien, R. V.; Khosla, C. Nichtproteinogene Aminosäurebausteine für Peptidgerüste aus nichtribosomalen Peptiden und hybriden Polyketiden. Angew. Chem. 2013, 125, 7238. (d) Lang, K.; Chin, J. W. Cellular incorporation of unnatural amino acids and bioorthogonal labeling of proteins. Chem. Rev. 2014, 114, 4764. (e) Martínez-Sáez, N.; Supekar, N. T.; Wolfert, M. A.; Bermejo, I. A.; Hurtado-Guerrero, R.; Asensio, J. L.; Jiménez-Barbero, J.; Busto, J. H.; Avenoza, A.; Boons, G. J.; Peregrina, J. M.; Corzana, F. Mucin architecture behind the immune response: design, evaluation and conformational analysis of an antitumor vaccine derived from an unnatural MUC1 fragment. Chem. Sci. 2016, 7, 2294.

(2) (a) Han, J.; Konno, H.; Sato, T.; Soloshonok, V. A.; Izawa, K. Tailor-made amino acids in the design of small-molecule blockbuster drugs. *Eur. J. Med. Chem.* **2021**, 220, No. 113448. (b) Nájera, C.; Sansano, J. M. Catalytic asymmetric synthesis of α -amino acids. *Chem. Rev.* **2007**, 107, 4584. (c) Nájera, C.; Foubelo, F.; Sansano, J. M.; Yus, M. Stereodivergent routes in organic synthesis: carbohydrates, amino acids, alkaloids and terpenes. *Org. Biomol. Chem.* **2020**, 18, 1232.

(3) (a) Key, H. M.; Miller, S. J. Site- and stereoselective chemical editing of Thiostrepton by Rh-catalyzed conjugate arylation: new analogues and collateral enantioselective synthesis of amino acids. J. Am. Chem. Soc. 2017, 139, 15460. (b) Wright, T. H.; Bower, B. J.; Chalker, J. M.; Bernardes, G. J. L.; Wiewiora, R.; Ng, W.-L.; Raj, R.; Faulkner, S.; Vallée, M. R. J.; Phanumartwiwath, A.; Coleman, O. D.; Thézénas, M.-L.; Khan, M.; Galan, S. R. G.; Lercher, L.; Schombs, M. W.; Gerstberger, S.; Palm-Espling, M. E.; Baldwin, A. J.; Kessler, B. M.; Claridge, T. D. W.; Mohammed, S.; Davis, B. G. Posttranslational Mutagenesis: a Chemical Strategy for Exploring Protein Side-chain Diversity. Science 2016, 354, 597.

(4) Nair, S. K.; Rocke, B. N.; Sutton, S. Lithium, Magnesium, and Copper: Contemporary Applications of Organometallic Chemistry in the Pharmaceutical Industry. In *Synthetic Methods in Drug Discovery*; Royal Society of Chemistry, 2016; Chapter 11, Vol. 2, pp 1–74.

(5) (a) Aceña, J. L.; Sorochinsky, A. E.; Soloshonok, V. Asymmetric synthesis of α -amino acids via homologation of Ni(II) complexes of glycine Schiff bases. Part 3: Michael addition reactions and miscellaneous transformations. *Amino Acids* **2014**, *46*, 2047. (b) Ferrreira, P. M. T.; Maia, H. L. S.; Monteiro, L. S.; Sacramento, J. Michael addition of thiols, carbon nucleophiles and amines to dehydroamino acid and dehydropeptide derivatives. J. Chem. Soc., Perkin Trans. 1 **2001**, 3167.

(6) (a) Crespi, S.; Fagnoni, M. Generation of alkyl radicals: from the tyranny of tin to the photon democracy. *Chem. Rev.* 2020, *120*, 9790.
(b) King, T. A.; Mandrup Kandemir, J.; Walsh, S. J.; Spring, D. R. Photocatalytic methods for amino acid modification. *Chem. Soc. Rev.* 2021, *50*, 39.

(7) (a) Constantin, T.; Zanini, M.; Regni, A.; Sheikh, N. S.; Juliá, F.; Leonori, D. Aminoalkyl radicals as halogen-atom transfer agents for activation of alkyl and aryl halides. *Science* **2020**, *367*, 1021. (b) Shah, A. A.; Kelly, M. J., III; Perkins, J. J. Access to unnatural α -amino acids via visible-light-mediated decarboxylative conjugate addition to dehydroalanine. Org. Lett. 2020, 22, 2196.

(8) (a) Ji, P.; Zhang, Y.; Dong, Y.; Huang, H.; Wei, Y.; Wang, W. Synthesis of enantioenriched α -deuterated α -amino acids enabled by an organophotocatalytic radical approach. Org. Lett. 2020, 22, 1557. (b) Zhang, O.; Schubert, J. W. Derivatization of amino acids and peptides via photoredox-mediated conjugate addition. J. Org. Chem. 2020, 85, 6225. (c) Delgado, J. A. C.; Correia, J. T. M.; Pissinati, E. F.; Paixão, M. W. Biocompatible Photoinduced Alkylation of Dehydroalanine for the synthesis of unnatural α -amino acids. Org. Lett. 2021, 23, 5251. (d) Liu, L.; Deng, Z.; Xu, K.; Jiang, P.; Du, H.; Tan, J. Access to deuterated unnatural α -amino acids and peptides by photochemical acyl radical addition. Org. Lett. 2021, 23, 5299. (e) Ashley, M. A.; Rovis, T. Photoredox-catalyzed deaminative alkylation via C-N bond activation of primary amines. J. Am. Chem. Soc. 2020, 142, 18310. (f) Wang, X.; Chen, Y.; Song, H.; Liu, Y.; Wang, Q. Synthesis of unnatural α -amino acids via photoinduced decatungstate-catalyzed Giese reactions of aldehydes. Org. Lett. 2021, 23, 2199. (g) Merkens, K.; Aguilar Troyano, F. J.; Anwar, K.; Gómez-Suárez, A. Synthesis of γ -oxo- α -amino acids via radical acylation with carboxylic acids. J. Org. Chem. 2021, 86, 8448. (h) Merkens, K.; Aguilar Troyano, F. J.; Djossou, J.; Gómez-Suárez, A. Synthesis of unnatural α -amino acid derivatives via light-mediated radical decarboxylative processes. Adv. Synth. Catal. 2020, 362, 2354. (i) Yin, H.; Zheng, M.; Chen, H.; Wang, S.; Zhow, Q.; Zhang, Q.; Wang, P. Stereoselective and Divergent Construction of β -Thiolated/ Selenolated Amino Acids via Photoredox-Catalyzed Asymmetric Giese Reaction. J. Am. Chem. Soc. 2020, 142, 14201.

(9) Axon, J. R.; Beckwith, A. L. J. Diastereoselective radical addition to methyleneoxazolidinones: an enantioselective route to α -amino acids. J. Chem. Soc., Chem. Commun. **1995**, 549.

(10) (a) Gutiérrez-Jiménez, M. I.; Aydillo, C.; Navo, C. D.; Avenoza, A.; Corzana, F.; Jiménez-Osés, G.; Zurbano, M. M.; Busto, J. H.; Peregrina, J. M. Bifunctional chiral dehydroalanines for peptide coupling and stereoselective S-Michael addition. Org. Lett. **2016**, 18, 2796. (b) Navo, C. D.; Mazo, N.; Oroz, P.; Gutiérrez-Jiménez, M. I.; Marín, J.; Asenjo, J.; Avenoza, A.; Busto, J. H.; Corzana, F.; Zurbano, M. M.; Jiménez-Osés, G.; Peregrina, J. M. Synthesis of N- β substituted α , β -diamino acids via stereoselective N-Michael additions to a chiral bicyclic dehydroalanine. J. Org. Chem. **2020**, 85, 3134. (c) Oroz, P.; Navo, C. D.; Avenoza, A.; Busto, J. H.; Corzana, F.; Jiménez-Osés, G.; Peregrina, J. M. Toward enantiomerically pure β seleno- α -amino acids via stereoselective Se-Michael additions to chiral dehydroalanines. Org. Lett. **2021**, 23, 1955.

(11) (a) Aydillo, C.; Jiménez-Osés, G.; Busto, J. H.; Peregrina, J. M.; Zurbano, M. M.; Avenoza, A. Theoretical evidence for pyramidalized bicyclic serine enolates in highly diastereoselective alkylations. *Chem.* -*Eur. J.* **2007**, *13*, 4840. (b) Jiménez-Osés, G.; Aydillo, C.; Busto, J. H.; Zurbano, M. M.; Peregrina, J. M.; Avenoza, A. Role of the countercation in diastereoselective Alkylations of Pyramidalized Bicyclic Serine Enolates. An Easy Approach to α -Benzylserine. *J. Org. Chem.* **2007**, *72*, 5399.

(12) (a) Moozeh, K.; So, S. M.; Chin, J. Catalytic Stereoinversion of L-Alanine to Deuterated D-Alanine. *Angew. Chem., Int. Ed.* **2015**, *54*, 9381. (b) Loh, Y. Y.; Nagao, K.; Hoover, A. J.; Hesk, D.; Rivera, N. R.; Colletti, S. L.; Davies, I. W.; MacMillan, D. W. C. Photoredox-Catalyzed Deuteration and Tritiation of Pharmaceutical Compounds. *Science* **2017**, *358*, 1182.

(13) (a) Saghiyan, A. S.; Geolchanyan, A. V. Asymmetric synthesis of all possible stereoisomers of 4-aminoglutamic acid via Michael condensation of chiral Ni(II) complexes of glycine and dehydroalanine. Synth. Commun. 2006, 36, 3667–3677. (b) Avenoza, A.; Cativiela, C.; Peregrina, J. M.; Zurbano, M. M. Asymmetric synthesis of meso- and (2R,4R)-2,4-diaminoglutaric acids. Tetrahedron: Asymmetry 1997, 8, 863–871. (c) Kabat, M. M. Radical reaction of Williams' glycinate auxiliaries with α -amidoacrylates: synthesis of orthogonally functionalized (2R,4R)- and (2R,4S)-diaminoglutamic acid. Tetrahedron Lett. 2001, 42, 7521.

(14) Che, Y.; Marshall, G. R. Engineering cyclic tetrapeptides containing chimeric amino acids as preferred reverse-turn scaffolds. *J. Med. Chem.* **2006**, *49*, 111.

(15) Mantas, M. J. Q.; Nunn, P. B.; Ke, Z.; Codd, G. A.; Barker, D. Genomic insights into the biosynthesis and physiology of the cyanobacterial neurotoxin 2,4-diaminobutanoic acid (2,4-DAB). *Phytochemistry* **2021**, *192*, No. 112953.

(16) Blind, P.-J.; Waldenstroem, A.; Hafstroem, L.; Berggren, D.; Ronquist, G. Unique antitumor effects of L-2,4 diaminobutyric acid on cultured hepatoma cells. *Anticancer Res.* **2003**, *23*, 1245.

(17) (a) Xue, Y.-P.; Cao, C.-H.; Zheng, Y.-G. Enzymatic asymmetric synthesis of chiral amino acids. *Chem. Soc. Rev.* **2018**, 47, 1516. (b) Wu, T.; Mu, X.; Xue, Y.; Xu, Y.; Nie, Y. Structure-guided steric hindrance engineering of Bacillus badius phenylalanine dehydrogenase for efficient L-homophenylalanine synthesis. *Biotechnol. Biofuels* **2021**, *14*, 207.

(18) (a) Rogers, J. M.; Passioura, T.; Suga, H. Nonproteinogenic deep mutational scanning of linear and cyclic peptides. *Proc. Natl. Acad. Sci. U.S.A.* **2018**, *115*, 10959. (b) Liu, Y. E.; Lu, Z.; Li, B.; Tian, J.; Liu, F.; Zhao, J.; Hou, C.; Li, Y.; Niu, L.; Zhao, B. Enzyme-inspired axially chiral pyridoxamines armed with a cooperative lateral amine chain for enantioselective biomimetic transamination. *J. Am. Chem. Soc.* **2016**, *138*, 10730.

(19) (a) Dardashti, R. N.; Metanis, N. Revisiting ligation at selenomethionine: Insights into native chemical ligation at selenocysteine and homoselenocysteine. *Bioorg. Med. Chem.* 2017, 25, 4983.
(b) Roelfes, G.; Hilvert, D. Incorporation of selenomethionine into proteins via selenohomocysteine-mediated ligation. *Angew. Chem., Int. Ed.* 2003, 115, 2377. (c) Siebum, A. H. G.; Woo, W. S.; Raap, J.; Lugtenburg, J. Access to any Site-Directed isotopomer of methionine, selenomethionine, cysteine, and selenocysteine - Use of simple, efficient modular synthetic reaction schemes for isotope incorporation. *Eur. J. Org. Chem.* 2004, 2004, 2905. (d) Xiao, Y.; Lee, K.; Liu, P. Syntheses of the P-methylase substrates of the bialaphos biosynthetic pathway. *Org. Lett.* 2008, 10, 5521.

(20) Li, X.; Curran, D. P. Diverging chemoselective reactions of separable amide rotational isomers. *Org. Lett.* **2010**, *12*, 612.

(21) Köse, A.; Gündoğdu, Ö.; Aktaş, D.; Fistikçi, M.; Altundaş, R.; Seçen, H.; Kara, Y. Enantiospecific synthesis of (*R*)-3-amino-4-(2,4,5trifluorophenyl)butanoic acid using (*S*)-serine as a chiral pool. *Helv. Chim. Acta* **2015**, *98*, 260.

(22) Sheldrick, G. M. SHELXL97: Program for the Refinement of Crystal Structures; University of Göttingen: Göttingen, Germany, 1997.

(23) Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Petersson, G. A.; Nakatsuji, H.; Li, X.; Caricato, M.; Marenich, A. V.; Bloino, J.; Janesko, B. G.; Gomperts, R.; Mennucci, B.; Hratchian, H. P.; Ortiz, J. V.; Izmaylov, A. F.; Sonnenberg, J. L.; Williams-Young, D.; Ding, F.; Lipparini, F.; Egidi, F.; Goings, J.; Peng, B.; Petrone, A.; Henderson, T.; Ranasinghe, D.; Zakrzewski, V. G.; Gao, J.; Rega, N.; Zheng, G.; Liang, W.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Throssell, K.; Montgomery, J. A., Jr.; Peralta, J. E.; Ogliaro, F.; Bearpark, M. J.; Heyd, J. J.; Brothers, E. N.; Kudin, K. N.; Staroverov, V. N.; Keith, T. A.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A. P.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Millam, J. M.; Klene, M.; Adamo, C.; Cammi, R.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Farkas, O.; Foresman, J. B.; Fox, D. J.; et al. Gaussian 16, revision C.01; Gaussian, Inc.: Wallingford, CT, 2016.

(24) Zhao, Y.; Truhlar, D. G. The M06 suite of density functionals for main group thermochemistry, thermochemical kinetics, non-covalent interactions, excited states, and transition elements: two new functionals and systematic testing of four M06-class functionals and 12 other functionals. *Theor. Chem. Acc.* **2008**, *120*, 215.

(25) Scalmani, G.; Frisch, M. J. Continuous surface charge polarizable continuum models of solvation. I. General formalism. *J. Chem. Phys.* **2010**, *132*, No. 114110.

(26) Ribeiro, R. F.; Marenich, A. V.; Cramer, C. J.; Truhlar, D. G. Use of Solution-Phase Vibrational Frequencies in Continuum Models for the Free Energy of Solvation. *J. Phys. Chem. B* **2011**, *115*, 14556–14562.

(27) Hratchian, H. P.; Schlegel, H. B. Following Reaction Pathways Using a Damped Classical Trajectory Algorithm. *J. Phys. Chem. A* **2002**, *106*, 165.